These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16861118)

  • 21. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
    Pinthus JH; Witkos M; Fleshner NE; Sweet J; Evans A; Jewett MA; Krahn M; Alibhai S; Trachtenberg J
    J Urol; 2006 Sep; 176(3):979-84; discussion 984. PubMed ID: 16890675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy.
    DeCastro GJ; McCann T; Benson MC; McKiernan JM
    Urology; 2008 Dec; 72(6):1214-8. PubMed ID: 18597825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial comment on: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Korfage IJ
    Eur Urol; 2009 Feb; 55(2):432. PubMed ID: 18783875
    [No Abstract]   [Full Text] [Related]  

  • 28. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy.
    Cheng L; Davidson DD; Lin H; Koch MO
    Cancer; 2007 Nov; 110(9):1967-72. PubMed ID: 17823907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short- and long-term mortality with localized prostate cancer.
    Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
    Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: Prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial.
    Schulz RJ; Kagan AR
    J Natl Cancer Inst; 2009 Jan; 101(2):124. PubMed ID: 19141784
    [No Abstract]   [Full Text] [Related]  

  • 34. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era.
    Mann MJ; DeCastro GJ; Desai M; Benson MC; McKiernan JM
    Urology; 2008 Dec; 72(6):1203-7. PubMed ID: 18674807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of a map in radical prostatectomy specimen allows visual estimation of tumor volume.
    Bettendorf O; Oberpenning F; Köpke T; Heinecke A; Hertle L; Boecker W; Semjonow A
    Eur J Surg Oncol; 2007 Apr; 33(3):352-7. PubMed ID: 17175129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
    BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.